Identification of Potential Biomarkers for Thyroid Cancer Using Bioinformatics Strategy: A Study Based on GEO Datasets

Abstract

Background. The molecular mechanisms and genetic markers of thyroid cancer are unclear. In this study, we used bioinformatics to screen for key genes and pathways associated with thyroid cancer development and to reveal its potential molecular mechanisms. Methods. The GSE3467, GSE3678, GSE33630, and GSE53157 expression profiles downloaded from the Gene Expression Omnibus database (GEO) contained a total of 164 tissue samples (64 normal thyroid tissue samples and 100 thyroid cancer samples). The four datasets were integrated and analyzed by the RobustRankAggreg (RRA) method to obtain differentially expressed genes (DEGs). Using these DEGs, we performed gene ontology (GO) functional annotation, pathway analysis, protein-protein interaction (PPI) analysis and survival analysis. Then, CMap was used to identify the candidate small molecules that might reverse thyroid cancer gene expression. Results. By integrating the four datasets, 330 DEGs, including 154 upregulated and 176 downregulated genes, were identified. GO analysis showed that the upregulated genes were mainly involved in extracellular region, extracellular exosome, and heparin binding. The downregulated genes were mainly concentrated in thyroid hormone generation and proteinaceous extracellular matrix. Pathway analysis showed that the upregulated DEGs were mainly attached to ECM-receptor interaction, p53 signaling pathway, and TGF-beta signaling pathway. Downregulation of DEGs was mainly involved in tyrosine metabolism, mineral absorption, and thyroxine biosynthesis. Among the top 30 hub genes obtained in PPI network, the expression levels of FN1, NMU, CHRDL1, GNAI1, ITGA2, GNA14 and AVPR1A were associated with the prognosis of thyroid cancer. Finally, four small molecules that could reverse the gene expression induced by thyroid cancer, namely ikarugamycin, adrenosterone, hexamethonium bromide and clofazimine, were obtained in the CMap database. Conclusion. The identification of the key genes and pathways enhances the understanding of the molecular mechanisms for thyroid cancer. In addition, these key genes may be potential therapeutic targets and biomarkers for the treatment of thyroid cancer.

A Prognostic Nomogram Model Based on mRNA Expression of DNA Methylation-Driven Genes for Gastric Cancer

“…GNAI1 belonged to the Gai family, which primarily functioned as inhibitors of adenylyl cyclase. GNAI1 was reported to confer hydrogen peroxide-induced apoptosis in human lung cancer cells and be associated with the prognosis of thyroid cancer patients (29,30). However, the biological functions of GNAI1 in GC remained unclear.…”

Identification and analysis of key genes associated with acute myocardial infarction by integrated bioinformatics methods

“…Using bioinformatics strategy, Shen et al found that fibronectin (FN1), neuromedin-U (NMU), chordin-like protein (CHRDL1), guanine nucleotide-binding protein subunit alpha-14 (GNA14), vasopressin V1a receptor (AVPR1A), guanine nucleotide-binding protein G(i) subunit alpha-1 (GNAI1), and integrin alpha-2 (ITGA2) may be potential biomarkers for the treatment of thyroid cancer. [ 16 ] Zou et al clarified that zinc finger protein 566 (ZNF566), zinc finger homeobox protein 3 (ZFHX3), PDZK1-interacting protein 1 (PDZK1IP1), and pituitary homeobox 2 (PITX2) are significantly associated with new biomarkers of atrial fibrillation-related stroke through the bioinformatics analysis of gene expression Omnibus (GEO) dataset. [ 17 ] Besides, Qian et al analyzed the microarray data of GSE59867 and found that proto-oncogene c-Fos (FOS), integrin alpha-IIb (ITGA2B), thrombospondin-1 (THBS1), and interleukin-8 (CXCL8) may play a vital role in development of heart failure after acute ST-segment elevation myocardial infarction.…”

Pattern Recognition Receptor based Prognostic Biomarkers for predicting Survival of Uterine Corpus Endometrial Cancer Patients

“…The choice of therapy is a very crucial step after the identification of genes that play a critical role. Thus, we extracted drug molecules which could re-modulate the overexpressed and underexpressed genes, using the ‘Cmap2 database [45,46] as done in [47]. We queried a list of probe ids corresponding to upregulated genes (CLEC1B, CLEC3A, FCN1, NLRP10) and downregulated genes (RIPK2, SARM1, IRF7, CTSB, NLRP9) as input to Cmap2.…”